Haverford Trust Co. Purchases 14,776 Shares of GlaxoSmithKline plc (GSK)
Haverford Trust Co. grew its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 4.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 387,938 shares of the pharmaceutical company’s stock after purchasing an additional 14,776 shares during the quarter. Haverford Trust Co.’s holdings in GlaxoSmithKline were worth $16,212,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. Morgan Stanley increased its holdings in GlaxoSmithKline by 16.5% in the third quarter. Morgan Stanley now owns 4,212,892 shares of the pharmaceutical company’s stock valued at $169,232,000 after purchasing an additional 597,367 shares during the period. We Are One Seven LLC acquired a new stake in GlaxoSmithKline in the fourth quarter valued at $98,000. River Wealth Advisors LLC increased its holdings in GlaxoSmithKline by 17.8% in the fourth quarter. River Wealth Advisors LLC now owns 1,990 shares of the pharmaceutical company’s stock valued at $76,000 after purchasing an additional 301 shares during the period. CWM LLC increased its holdings in GlaxoSmithKline by 27.0% in the fourth quarter. CWM LLC now owns 2,847 shares of the pharmaceutical company’s stock valued at $109,000 after purchasing an additional 605 shares during the period. Finally, Graves Light Private Wealth Management Inc. acquired a new stake in GlaxoSmithKline in the fourth quarter valued at $233,000. 11.31% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have commented on GSK shares. UBS Group cut shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Friday, February 22nd. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research report on Tuesday, April 23rd. Finally, Shore Capital cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $41.83.
GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 EPS for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.13. The business had revenue of $9.98 billion for the quarter, compared to analysts’ expectations of $9.86 billion. GlaxoSmithKline had a net margin of 12.27% and a return on equity of 171.27%. As a group, sell-side analysts predict that GlaxoSmithKline plc will post 2.92 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a dividend of $0.4953 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $1.98 dividend on an annualized basis and a dividend yield of 4.93%. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 61.71%.
In related news, Director Plc Glaxosmithkline acquired 325,000 shares of the business’s stock in a transaction dated Monday, April 22nd. The shares were bought at an average price of $18.00 per share, with a total value of $5,850,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. 10.00% of the stock is owned by corporate insiders.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: How Investors Can Profit from Options Trading
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.